Switch to:
Also traded in: Canada

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.65
MSLI's Cash to Debt is ranked lower than
63% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. MSLI: 0.65 )
Ranked among companies with meaningful Cash to Debt only.
MSLI' s Cash to Debt Range Over the Past 10 Years
Min: 0.09  Med: 10.33 Max: No Debt
Current: 0.65
Equity to Asset 0.69
MSLI's Equity to Asset is ranked higher than
61% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MSLI: 0.69 )
Ranked among companies with meaningful Equity to Asset only.
MSLI' s Equity to Asset Range Over the Past 10 Years
Min: 0.2  Med: 0.61 Max: 0.94
Current: 0.69
0.2
0.94
Interest Coverage 1.50
MSLI's Interest Coverage is ranked lower than
94% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 123.58 vs. MSLI: 1.50 )
Ranked among companies with meaningful Interest Coverage only.
MSLI' s Interest Coverage Range Over the Past 10 Years
Min: 1.01  Med: 12.40 Max: 23.79
Current: 1.5
1.01
23.79
F-Score: 6
Z-Score: 1.57
M-Score: -1.14
WACC vs ROIC
19.70%
3.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 12.66
MSLI's Operating margin (%) is ranked higher than
62% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. MSLI: 12.66 )
Ranked among companies with meaningful Operating margin (%) only.
MSLI' s Operating margin (%) Range Over the Past 10 Years
Min: -360.47  Med: -27.84 Max: 19.4
Current: 12.66
-360.47
19.4
Net-margin (%) -0.48
MSLI's Net-margin (%) is ranked lower than
74% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. MSLI: -0.48 )
Ranked among companies with meaningful Net-margin (%) only.
MSLI' s Net-margin (%) Range Over the Past 10 Years
Min: -396.76  Med: -37.02 Max: 22.08
Current: -0.48
-396.76
22.08
ROE (%) -0.17
MSLI's ROE (%) is ranked lower than
70% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. MSLI: -0.17 )
Ranked among companies with meaningful ROE (%) only.
MSLI' s ROE (%) Range Over the Past 10 Years
Min: -90.89  Med: -15.85 Max: 5.02
Current: -0.17
-90.89
5.02
ROA (%) -0.11
MSLI's ROA (%) is ranked lower than
69% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. MSLI: -0.11 )
Ranked among companies with meaningful ROA (%) only.
MSLI' s ROA (%) Range Over the Past 10 Years
Min: -48.82  Med: -12.42 Max: 4.57
Current: -0.11
-48.82
4.57
ROC (Joel Greenblatt) (%) 107.03
MSLI's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. MSLI: 107.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MSLI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -652.31  Med: -115.07 Max: 94.84
Current: 107.03
-652.31
94.84
Revenue Growth (3Y)(%) 6.30
MSLI's Revenue Growth (3Y)(%) is ranked higher than
51% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. MSLI: 6.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MSLI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -64.2  Med: -2.75 Max: 86.8
Current: 6.3
-64.2
86.8
EPS Growth (3Y)(%) -85.10
MSLI's EPS Growth (3Y)(%) is ranked lower than
99% of the 487 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. MSLI: -85.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MSLI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -85.1  Med: -8.50 Max: 108
Current: -85.1
-85.1
108
» MSLI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

MSLI Guru Trades in Q3 2014

Jim Simons 358,400 sh (-39.04%)
» More
Q4 2014

MSLI Guru Trades in Q4 2014

Jim Simons 328,700 sh (-8.29%)
» More
Q1 2015

MSLI Guru Trades in Q1 2015

Jim Simons 436,200 sh (+32.70%)
» More
Q2 2015

MSLI Guru Trades in Q2 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MSLI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Merus Labs International Inc

Slow Growth Ahead; Updates on Merus Labs International, Enghouse Systems, Athabasca Minerals Commentary and updates on previous recommendations
We are joined this week by contributing editor Ryan Irvine, who gives us his outlook for the markets and updates some previous recommendations. Ryan is the CEO of KeyStone Financial (www.KeyStocks.com) and is one of the country’s top experts in small-cap stocks. He is based in the Vancouver area. Here is his report. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 469.97
MSLI's P/E(ttm) is ranked lower than
98% of the 499 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.00 vs. MSLI: 469.97 )
Ranked among companies with meaningful P/E(ttm) only.
MSLI' s P/E(ttm) Range Over the Past 10 Years
Min: 5.98  Med: 14.21 Max: 570
Current: 469.97
5.98
570
Forward P/E 21.28
MSLI's Forward P/E is ranked lower than
51% of the 236 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.62 vs. MSLI: 21.28 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.06
MSLI's P/B is ranked higher than
85% of the 706 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. MSLI: 1.06 )
Ranked among companies with meaningful P/B only.
MSLI' s P/B Range Over the Past 10 Years
Min: 0.29  Med: 0.77 Max: 2.62
Current: 1.06
0.29
2.62
P/S 3.42
MSLI's P/S is ranked lower than
59% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. MSLI: 3.42 )
Ranked among companies with meaningful P/S only.
MSLI' s P/S Range Over the Past 10 Years
Min: 0.84  Med: 3.15 Max: 31.31
Current: 3.42
0.84
31.31
POCF 8.18
MSLI's POCF is ranked higher than
86% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.79 vs. MSLI: 8.18 )
Ranked among companies with meaningful POCF only.
MSLI' s POCF Range Over the Past 10 Years
Min: 1.3  Med: 6.92 Max: 99999999.99
Current: 8.18
1.3
99999999.99
EV-to-EBIT 34.61
MSLI's EV-to-EBIT is ranked lower than
73% of the 515 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.63 vs. MSLI: 34.61 )
Ranked among companies with meaningful EV-to-EBIT only.
MSLI' s EV-to-EBIT Range Over the Past 10 Years
Min: -167.2  Med: 0.20 Max: 232.2
Current: 34.61
-167.2
232.2
EV-to-EBITDA 6.83
MSLI's EV-to-EBITDA is ranked higher than
89% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.42 vs. MSLI: 6.83 )
Ranked among companies with meaningful EV-to-EBITDA only.
MSLI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -155.7  Med: 0.70 Max: 28.3
Current: 6.83
-155.7
28.3
Current Ratio 2.41
MSLI's Current Ratio is ranked higher than
53% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. MSLI: 2.41 )
Ranked among companies with meaningful Current Ratio only.
MSLI' s Current Ratio Range Over the Past 10 Years
Min: 0.38  Med: 1.36 Max: 14.42
Current: 2.41
0.38
14.42
Quick Ratio 2.15
MSLI's Quick Ratio is ranked higher than
61% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. MSLI: 2.15 )
Ranked among companies with meaningful Quick Ratio only.
MSLI' s Quick Ratio Range Over the Past 10 Years
Min: 0.31  Med: 1.36 Max: 14.42
Current: 2.15
0.31
14.42
Days Inventory 180.02
MSLI's Days Inventory is ranked lower than
75% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.46 vs. MSLI: 180.02 )
Ranked among companies with meaningful Days Inventory only.
MSLI' s Days Inventory Range Over the Past 10 Years
Min: 153.34  Med: 238.60 Max: 334.61
Current: 180.02
153.34
334.61
Days Sales Outstanding 101.74
MSLI's Days Sales Outstanding is ranked lower than
68% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. MSLI: 101.74 )
Ranked among companies with meaningful Days Sales Outstanding only.
MSLI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 15.32  Med: 93.85 Max: 200.98
Current: 101.74
15.32
200.98

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.68
MSLI's Price/Projected FCF is ranked higher than
68% of the 313 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. MSLI: 1.68 )
Ranked among companies with meaningful Price/Projected FCF only.
MSLI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.17  Med: 0.90 Max: 2.09
Current: 1.68
0.17
2.09
Price/Median PS Value 1.12
MSLI's Price/Median PS Value is ranked higher than
55% of the 612 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. MSLI: 1.12 )
Ranked among companies with meaningful Price/Median PS Value only.
MSLI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.03  Med: 0.81 Max: 8
Current: 1.12
0.03
8
Price/Graham Number 16.25
MSLI's Price/Graham Number is ranked lower than
98% of the 479 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.07 vs. MSLI: 16.25 )
Ranked among companies with meaningful Price/Graham Number only.
MSLI' s Price/Graham Number Range Over the Past 10 Years
Min: 0.1  Med: 1.59 Max: 14.33
Current: 16.25
0.1
14.33
Earnings Yield (Greenblatt) (%) 2.89
MSLI's Earnings Yield (Greenblatt) (%) is ranked lower than
52% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MSLI: 2.89 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MSLI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.4  Med: 57.50 Max: 5232.3
Current: 2.89
0.4
5232.3

More Statistics

Revenue(Mil) $39
Beta2.01
Short Percentage of Float1.47%
52-Week Range $1.06 - 2.85
Shares Outstanding(Mil)102.30

Analyst Estimate

Sep16 Sep17 Sep18
Revenue(Mil) 50 55 48
EPS($) -0.00 0.04 0.02
EPS without NRI($) -0.00 0.04 0.02

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:MSL.Canada,
Merus Labs International Inc was incorporated on October 1, 2012 in British Columbia. The Company is a specialty pharmaceutical company. It acquires prescription medicines in various categories which include on patent but at maturity stage of product life cycle; branded generics; under promoted products; Niche market pharmaceuticals; and products with annual sales below critical threshold for large pharma. The Company competes with multinational pharmaceutical development corporations to small, single product companies that may limit their activities to a particular therapeutic area or region or territory.
» More Articles for MSLI

Headlines

Articles On GuruFocus.com
Slow Growth Ahead; Updates on Merus Labs International, Enghouse Systems, Athabasca Minerals Oct 05 2015 
Update on Merus Labs International, Athabasca Minerals Inc, Enghouse Systems Limited, WiLAN Inc. Jun 22 2015 
Merus Labs International: A Pharma Stock With Growth Potential Mar 30 2015 

More From Other Websites
Merus completes acquisition of Elantan®, Isoket® and Deponit® rights from UCB and announces date... Feb 04 2016
Merus completes acquisition of Elantan®, Isoket® and Deponit® rights from UCB and announces date... Feb 04 2016
Merus Reaches Agreement to Acquire Three Cardiovascular Products Feb 01 2016
Merus Reaches Agreement to Acquire Three Cardiovascular Products Feb 01 2016
MERUS LABS INTERNATIONAL INC. Financials Jan 05 2016
Merus Reports Fiscal 2015 Results and Provides Business Update Dec 07 2015
Merus Reports Fiscal 2015 Results and Provides Business Update Dec 07 2015
Merus Labs to Host Conference Call on Year End Results Dec 01 2015
Merus Labs to Host Conference Call on Year End Results Dec 01 2015
Merus Labs International (MSLI) Jumps: Stock Rises 6.4% Nov 20 2015
Merus Labs Announces Filing of Audited June 30, 2015 Financial Statements Oct 21 2015
Merus Labs Announces Filing of Audited June 30, 2015 Financial Statements Oct 21 2015
Slow Growth Ahead; Updates on Merus Labs International, Enghouse Systems, Athabasca Minerals Oct 05 2015
What Falling Estimates & Price Mean for Merus Labs International (MSLI) Sep 09 2015
Merus Labs Reports Q3 2015 Results Aug 10 2015
Merus Labs Reports Q3 2015 Results Aug 10 2015
Merus Labs Announces Filing of Preliminary Base Shelf Prospectus Jul 10 2015
Merus Labs Announces Filing of Preliminary Base Shelf Prospectus Jul 10 2015
Merus Labs Provides an Update on German Reimbursement Review Jun 03 2015
Merus Labs Provides an Update on German Reimbursement Review Jun 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK